EFFICACY AND SAFETY OF ORFORGLIPRON IN ADULTS WITH BODY MASS INDEX OF 27 TO LESS THAN 30 KG/M2 AND ADIPOSITY-RELATED COMPLICATIONS: A POST HOC ANALYSIS OF THE ATTAIN-1 TRIAL

Descargar Publicación
Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials GLP-1 based therapy of obesity and type 2 diabetes